Based on PCR technology acquired from Hain Diagnostics, the test and platform enable rapid detection of TB, as well as assessment of antibiotic resistance.
The firm said the purchase will allow it to better provide software tools to customers in the chemistry, pharmaceutical, and analytical laboratory markets.
The company reported revenues of $553.6 million, up from $530.5 million in Q4 2017, and beating the average analyst estimate of $544.6 million.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
Revenues in the third quarter grew to $466.6 million from $335.6 million in Q3 2017, beating the consensus Wall Street estimate of $451.7 million.
The group's meeting this week evidenced the ongoing shift towards analyzing proteins in the context of specific isoforms, complexes, and cells.
Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.
The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.
JPK provides microscopy instrumentation for biomolecular and cellular imaging, as well as force measurements on single molecules, cells, and tissues.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.